Apomorphine
| Apomorphine | |
|---|---|
| Salts [] | |
|---|---|
| Apomorphine dihydrochloride | |
| Apomorphine hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 267.32 g/mol [1] |
| Appearance | Hexagonal plates from chloroform+petroleum ether; rods from ether [1] |
| Melting point | 195 °C (decomposes) [1] |
| Decomposition | When heated to decomposition it emits highly toxic fumes of nitroxides. [1] |
| Solubility | MINUTE, WHITE OR GRAYISH WHITE, GLISTENING CRYSTALS OR WHITE POWDER; ODORLESS; SOLN ARE NEUTRAL TO LITMUS; LEVOROTATORY IN DIL ACID; 1 G SOL IN 50 ML WATER, IN ABOUT 50 ML ALCOHOL, & IN ABOUT 20 ML WATER @ 80 °C; PPT BY TANNIC ACID & OTHER ALKALOIDAL PRECIPITANTS & DECOMP BY OXIDIZING AGENTS. /HCL/ [1] |
| Predicted LogP | 2.3 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H17NO2 |
| IUPAC name | (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol |
| SMILES | CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O |
| InChI | InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1 |
| InChIKey | VMWNQDUVQKEIOC-CYBMUJFWSA-N |
| CAS number | 58-00-4 |
| UNII | N21FAR7B4S |
| PubChem CID | 6005 |
| Pharmacokinetics[] | |
|---|---|
| Onset | 10–20 min |
| Elimination half-life | 40 minutes |
| Duration of action | 60–90 min |
| Metabolism | Liver, phase II |
| Excretion | Liver |
| Routes of administration | Subcutaneous, sublingual |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - oral: 300 mg/kg - ip: 160 mg/kg - iv: 56 mg/kg - Intraperitoneal: 0.6 mmoles/kg [1] |
Apomorphine (also known as L-Apomorphine, Apomorfin, Apomorphin, R-(-)-Apomorphine, Ixense, (-)-Apomorphine, 6aβ-Aporphine-10,11-diol, Apomorphinum, (-)-10,11-Dihydroxyaporphine or Vr-040) is a substance of the 1,2-diarylethylamine class.
Chemistry
Salts []
Stereochemistry []
Apomorphine is a single defined stereoisomer (optical activity ( - )).
Druglikeness
Lipinski's rule of five
Apomorphine matches Lipinski's rule of five.Pharmacology
ATC Classification
- genito urinary system and sex hormones (G)
- urologicals (G04)
- urologicals (G04B)
- drugs used in erectile dysfunction (G04BE)
- apomorphine (G04BE07)
- nervous system (N)
- anti-parkinson drugs (N04)
- dopaminergic agents (N04B)
- dopamine agonists (N04BC)
- apomorphine (N04BC07)
MeSH Classification
Mechanism of action []
Apomorphine is a non-ergoline dopamine agonist with high binding affinity to dopamine D2, D3, and D5 receptors. Stimulation of D2 receptors in the caudate-putamen, a region of the brain responsible for locomotor control, may be responsible for apomorphine's action. However, the means by which the cellular effects of apomorphine treat hypomobility of Parkinson's remain unknown. [1]
Interactions []
Medical side effects []
52 side effects listed on drug labels in SIDER 4.1 (apomorphine).
- Yawning
- Somnolence
- Dyskinesia
- Nausea
- Vomiting
- Dizziness
- Syncope
- Orthostatic hypotension
- Nasopharyngitis
- Rhinorrhoea
- Contusion
- Angina pectoris
- Chest pain
- Confusional state
- Feeling abnormal
- Oedema
- Hallucination
- Swelling
- Granuloma
- Pruritus
- Anxiety
- Arthralgia
- Musculoskeletal discomfort
- Asthenia
- Fatigue
- Back pain
- Mental disorder
- Constipation
- Dehydration
- Diarrhoea
- Dyspnoea
- Ecchymosis
- Flushing
- Headache
- Cardiac failure congestive
- Hypotension
- Libido increased
- Disturbance in sexual arousal
- Pain in extremity
- Pallor
- Pathological gambling
- Pneumonia
- Priapism
- Psychotic disorder
- Shock
- Loss of consciousness
- Urinary tract infection
- Injection site reaction
- Hypersexuality
- Hyperhidrosis
- Parkinson's disease
- Insomnia
Indications
- Parkinson's disease
Subjective effects []
| emily / Apomorphine [] | |
|---|---|
Routes:
| |
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 6005, Apomorphine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/6005
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Apomorphine. UNII: N21FAR7B4S. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/N21FAR7B4S
Movapo Pod (Stada Pharmaceuticals Australia Pty Ltd). Therapeutic Goods Administration (TGA). 13 September 2024. https://www.tga.gov.au/resources/prescription-medicines-registrations/movapo-pod-stada-pharmaceuticals-australia-pty-ltd
Onapgo- apomorphine hydrochloride injection, solution. DailyMed. 28 February 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3552b6e-5ae7-4993-aa1a-e399c4a7080a
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 06:18:09 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 06:18:05 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 06:18:05 |
| gsrs | ok | 2026-11-20 06:18:07 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014852) | 2026-11-20 06:18:05 |
| kegg | ok | 2026-11-20 06:18:08 |
| pubchem | ok | 2026-11-20 06:18:04 |
| missing (no r/tripreports posts mention it) | 2026-11-20 06:18:05 | |
| sider | ok | 2026-11-20 06:18:05 |
| structure | ok | 2026-11-20 06:18:05 |
| wikipedia | ok | 2026-11-20 06:18:05 |